Pharsight

Drugs that contain Ertugliflozin; Sitagliptin Phosphate

1. Steglujan patents expiration

STEGLUJAN's oppositions filed in EPO
STEGLUJAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

US8080580 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6699871

(Pediatric)

MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 4 months ago)

US7326708

(Pediatric)

MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)

US9308204 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(6 years from now)

US9439901 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-275) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 19, 2022

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: Ertugliflozin in combination with sitagliptin and in further combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Ertuglif...

Dosage: TABLET;ORAL

More Information on Dosage

STEGLUJAN family patents

Family Patents